» Articles » PMID: 19749797

Thyroid Hormone Receptor Mutants Implicated in Human Hepatocellular Carcinoma Display an Altered Target Gene Repertoire

Overview
Journal Oncogene
Date 2009 Sep 15
PMID 19749797
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Thyroid hormone receptors (TRs) are hormone-regulated transcription factors that control multiple aspects of normal physiology and development. Mutations in TRs have been identified at high frequency in certain cancers, including human hepatocellular carcinomas (HCCs). The majority of HCC-TR mutants bear lesions within their DNA recognition domains, and we have hypothesized that these lesions change the mutant receptors' target gene repertoire in a way crucial to their function as oncoproteins. Using stable cell transformants and expression array analysis, we determined that mutant TRs isolated from two different HCCs do, as hypothesized, display a target gene repertoire distinct from that of their normal TR progenitors. Only a subset of genes regulated by wild-type TRs was regulated by the corresponding HCC-TR mutants. More surprisingly, the HCC-TR mutants also gained the ability to regulate additional target genes not recognized by the wild-type receptors, and were not simply restricted to repression, but could also activate a subset of their target genes. We conclude that the TR mutants isolated from HCC have sustained multiple alterations from their normal progenitors that include not only changes in their transcriptional outputs, but also changes in the genes they target; both are likely to contribute to neoplasia.

Citing Articles

Actions of thyroid hormones and thyromimetics on the liver.

Sinha R, Bruinstroop E, Yen P Nat Rev Gastroenterol Hepatol. 2024; 22(1):9-22.

PMID: 39420154 PMC: 7616774. DOI: 10.1038/s41575-024-00991-4.


Protective effect of higher free thyroxine levels within the reference range on biliary tract cancer risk: a multivariable mendelian randomization and mediation analysis.

Chen Y, Dong H, Qu B, Ma X, Lu L Front Endocrinol (Lausanne). 2024; 15:1379607.

PMID: 38686204 PMC: 11056546. DOI: 10.3389/fendo.2024.1379607.


Mislocalization of Cancer-associated Thyroid Hormone Receptor Mutants.

Salomon M, Malapati S, O Dwyer J, Silva C, Williams C, Barbeau M Nucl Receptor Res. 2022; 2020.

PMID: 35280700 PMC: 8909557.


Thyroid Hormone in Hepatocellular Carcinoma: Cancer Risk, Growth Regulation, and Anticancer Drug Resistance.

Lin Y, Lin K, Yeh C Front Med (Lausanne). 2020; 7:174.

PMID: 32528965 PMC: 7258858. DOI: 10.3389/fmed.2020.00174.


The Role of Thyroid Hormones in Hepatocyte Proliferation and Liver Cancer.

Gionfra F, De Vito P, Pallottini V, Lin H, Davis P, Pedersen J Front Endocrinol (Lausanne). 2019; 10:532.

PMID: 31543862 PMC: 6730500. DOI: 10.3389/fendo.2019.00532.


References
1.
Lin K, Shieh H, Chen S, Hsu H . Expression of mutant thyroid hormone nuclear receptors in human hepatocellular carcinoma cells. Mol Carcinog. 1999; 26(1):53-61. DOI: 10.1002/(sici)1098-2744(199909)26:1<53::aid-mc7>3.0.co;2-z. View

2.
Mikheev A, Mikheeva S, Maxwell J, Rivo J, Rostomily R, Swisshelm K . Dickkopf-1 mediated tumor suppression in human breast carcinoma cells. Breast Cancer Res Treat. 2007; 112(2):263-73. DOI: 10.1007/s10549-007-9867-2. View

3.
Refetoff S, Weiss R, Usala S . The syndromes of resistance to thyroid hormone. Endocr Rev. 1993; 14(3):348-99. DOI: 10.1210/edrv-14-3-348. View

4.
Murata Y . Multiple isoforms of thyroid hormone receptor: an analysis of their relative contribution in mediating thyroid hormone action. Nagoya J Med Sci. 1999; 61(3-4):103-15. View

5.
Tsai C, Fondell J . Nuclear receptor recruitment of histone-modifying enzymes to target gene promoters. Vitam Horm. 2004; 68:93-122. DOI: 10.1016/S0083-6729(04)68003-4. View